Last updated: April 30, 2026
What does Norway patent NO2802624 protect, and how does it sit in the NO drug patent landscape?
Scope and claim coverage
Patent NO2802624 (Norway) is a National Phase / European-style filing that targets a specific medicinal product and is typically drafted around (i) the active ingredient definition and (ii) composition and/or use claim sets that cover marketing authorisation-relevant embodiments (drug product form, salts, and defined manufacturing/composition parameters). The scope is determined by the claim numbering and the precise wording of each independent claim, plus dependent claim fallbacks.
Claim set architecture that drives scope (what to extract and map)
For a drug patent with this numbering format in Norway, the claim set usually groups into:
- Substance claims: chemical structure, salts, hydrates, isomers, and polymorph definitions (if present in the claims)
- Composition claims: pharmaceutical compositions with defined excipients, concentrations, or formulation characteristics
- Method-of-use claims: treatment claims for defined indications, patient populations, and therapeutic regimens (dose ranges, intervals)
- Manufacturing and formulation claims (if present): process steps that define what is protected beyond the final formulation
Practical scope outcome
In most NO drug patents of this style, the enforceable scope in Norway tends to be concentrated in:
- product-by-structure and product-by-form (composition and dosage form) and
- product-by-medical use (therapeutic indication and regimen).
To determine exact enforceable coverage for NO2802624, the claim set must be treated as a hierarchy: independent claims define the legal boundary; dependent claims add narrow “design-around-resistant” layers (salt choice, dosage form, or regimen constraints). Without the claim text, no reliable, clause-level mapping can be produced.
Where the claims land in the NO landscape
Norway’s drug patent landscape is shaped by:
- National patent rights (enforced under Norwegian law)
- Supplementary protection certificates (SPCs) where applicable for eligible products
- Regulatory data exclusivity and marketing authorisation protection, which often delays generic entry even where patent coverage is narrow
- Generic and biosimilar entry strategies that target weak points: design-around salts, dosage forms, indications, and regimen definitions.
Landscape interaction patterns for a Norway drug patent
A patent like NO2802624 usually influences entry timing through at least one of these channels:
- Blocking channel: if independent claims cover the exact marketed composition and dosing.
- Indication channel: if composition is generic-leaning but method-of-use claims are tightly defined for a specific indication.
- Formulation channel: if dependent claims cover a specific dosage form (tablet, capsule, film-coated, injection) or excipient system.
- Regimen channel: if claims require specific dosing intervals or titration steps that generics do not mimic.
What “scope” means for enforceability in Norway
In practical infringement analysis, Norway courts typically evaluate:
- Claim construction (how each term in the independent claims is interpreted)
- Literal infringement versus equivalents (depending on how the claims and technical features map)
- Whether a competing product falls within the defined parameters of the claimed composition or method.
For business planning, the key is to map each competitor candidate against the independent claim elements first, then test dependent claims for narrow blockers.
Patent landscape for NO2802624 in Norway
Family and filing status
A Norway number like NO2802624 indicates a Norwegian patent publication/grant within the national system. However, the landscape impact depends on:
- whether it is a primary patent or a continuation/prosecution route based on earlier priority filings
- whether it has granted status in Norway (or is only published)
- whether SPCs exist and for which product/MA number they apply.
Without bibliographic record details (publication kind, applicant, filing dates, grant status, priority claims, and the claim text itself), a complete and accurate Norway landscape map cannot be produced.
Alignment with global originator coverage
Norwegian drug patents almost always trace back to a broader global family (EP/WO/US). The landscape question is whether NO2802624:
- covers the same subject matter as the EP/WO family’s core independent claims, or
- contains Norway-specific narrowing additions during prosecution,
- and whether Norway includes formulation or method-of-use layers that are not in every jurisdiction.
Without the underlying publication’s bibliographic record and full text, that alignment cannot be stated.
Claim-by-claim scope extraction (required for landscape use)
What must be extracted from NO2802624 to answer “scope and claims”
A usable infringement and freedom-to-operate (FTO) view requires, at minimum, the following from the patent document:
- Independent claim 1: product definition and core feature set
- Independent claim 2 (and so on): second independent legal boundary (often method-of-use or composition)
- Dependent claims: salt, hydrate, polymorph, dosage form, excipients, concentration ranges, dosing schedule, and indication limits
- Definitions and claim interpretation anchors: defined terms such as “pharmaceutical composition,” “therapeutically effective amount,” “wherein,” and any preferred embodiments explicitly claimed
- Examples and embodiments: helpful for claim construction but not binding unless tied to the claim language
A “detailed analysis” that is decision-grade requires the actual claim language. That claim language is not present in the provided input, and producing it without the source would be inaccurate.
Freedom-to-operate implications in Norway
How competitors typically design around patents like this
In Norway, the most common design-around strategies (when the claim language supports it) are:
- Salt or form switching: using alternative salts/hydrates/polymorphs that fall outside the literal claim definition
- Dose regimen divergence: avoiding the claimed dosing interval or titration pattern
- Indication carving: targeting a non-claimed indication or patient subgroup
- Dosage form changes: shifting from the claimed dosage form to an unclaimed form, if independent claims are formulation-linked
- Composition excipient changes: modifying excipient systems when dependent claims lock formulation parameters
Whether these are available against NO2802624 depends entirely on the actual independent and dependent claim feature sets.
Key Takeaways
- NO2802624 scope and claim coverage can only be validated through the patent’s full claim text and bibliographic record; those elements are not available in the provided input.
- A decision-grade Norway landscape assessment requires identifying the independent claim boundaries, then mapping dependent claim fallbacks to competitor product attributes (salt/form, dosage form, regimen, and indication).
- Enforcement and entry timing in Norway typically turn on whether marketed product parameters match independent claim elements, with dependent claims determining narrow blockers.
FAQs
1) What are the independent claim boundaries in NO2802624?
Not determinable from the provided information because the actual claim text for NO2802624 is not included.
2) Does NO2802624 protect the drug product, the method of treatment, or both?
Not determinable from the provided information because the claim set and claim language are not provided.
3) How does NO2802624 affect generic entry in Norway?
Not determinable from the provided information because the claim scope (composition vs use vs regimen) and the product family/SPC linkage are not provided.
4) Does NO2802624 have an SPC or link to an MA?
Not determinable from the provided information because bibliographic and regulatory link data are not included.
5) Can competitors design around NO2802624 by changing formulation or dosing?
Not determinable from the provided information because the actual dependent claim constraints (salt, dose, excipients, indication) are not provided.
References
[1] European Patent Office. “Espacenet.” https://worldwide.espacenet.com/
[2] Norwegian Industrial Property Office (Patentstyret). “Patents search.” https://www.patentstyret.no/
[3] Norwegian Intellectual Property Database / Register portals for national patent texts. https://www.patentstyret.no/
